Immunorho

Human Anti-D Immunoglobulin, the active ingredient in Immunorho, is an Immunoglobulin presented as an injectable solution for intramuscular use. It prevents maternal immune sensitization to the D antigen in Rh‑negative pregnant women, thereby reducing the risk of hemolytic disease of the newborn.

GNH USA supplies Immunorho as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Immunorho, a human anti‑D immunoglobulin, works within the Rh‑D antigen pathway to prevent immune‑mediated complications. - Rh‑negative pregnancy: prevents maternal sensitization to RhD antigen, reducing risk of hemolytic disease of the newborn. - Neonatal care: given prophylactically to newborns at risk of Rh‑incompatible hemolysis. - Post‑partum management: administered after delivery of an Rh‑positive infant to avert alloimmunization.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the intramuscular site. - Low‑grade fever: transient temperature rise within 24 hours. - Headache: mild, self‑limiting. - Nausea: occasional mild gastrointestinal upset.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hemolysis: rapid destruction of red blood cells. - Serum sickness: immune complex–mediated reaction with rash and arthralgia. - Acute renal failure: rare but serious impairment of kidney function.

Immunorho should be used with careful clinical assessment. - Rh status verification: confirm maternal Rh‑negative status before administration. - IgA deficiency screening: avoid in patients with known IgA deficiency due to risk of severe reactions. - Allergy history: assess for prior hypersensitivity to blood products. - Concomitant blood products: avoid unless clinically indicated to reduce additive immune load. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human Anti‑D Immunoglobulin may interact with other agents. Major Interactions (Avoid): - Additional anti‑D immunoglobulins: risk of overdose and immune complex formation. - Live vaccines: may interfere with vaccine efficacy. - Immunosuppressive monoclonal antibodies: can diminish prophylactic effect. Moderate Interactions (Monitor Closely): - IgA‑containing blood products: heightened risk in IgA‑deficient individuals. - Antihistamines: may mask early signs of an allergic reaction. - Corticosteroids: could alter immune response to the prophylaxis.